Dianthus Therapeutics, Inc.
Ticker: DNTHHealthcarePharmaceutical PreparationsThe business
Dianthus Therapeutics, Inc. (Nasdaq: DNTH) is a clinical-stage biotechnology company dedicated to developing therapies for patients with severe autoimmune diseases. The company's website is www.dianthustx.com.
The company's lead clinical-stage candidate, claseprubart, is a monoclonal antibody engineered with extended half-life and high selectivity for active C1s complement protein. Claseprubart is designed to enable less frequent, self-administered subcutaneous injections suitable for pre-filled pens. The company is currently conducting three mid- to late-stage clinical trials with claseprubart in generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and multifocal motor neuropathy. In September 2025, the company reported positive top-line results from its Phase 2 MaGic trial in generalized myasthenia gravis patients, with plans to initiate a Phase 3 registrational trial in mid-2026. In March 2026, the company announced an early go announcement for its Phase 3 CAPTIVATE trial in chronic inflammatory demyelinating polyneuropathy after achieving target responder rates.
The company's second clinical-stage candidate, DNTH212, is a bifunctional fusion protein targeting plasmacytoid dendritic cell BDCA2 to reduce Type 1 interferon production while simultaneously inhibiting BAFF/APRIL to suppress B cell function. The company entered into an exclusive license agreement for DNTH212 in October 2025, with a Phase 1 study initiated in December 2025.
Dianthus was formed through a reverse merger completed on September 11, 2023, between Magenta Therapeutics, Inc. and Dianthus Therapeutics OpCo, Inc. The company holds worldwide development and commercialization rights to its product candidates outside of Greater China, where it has licensed claseprubart to Tenacia Biotechnology and DNTH212 to Nanjing Leads Biolabs. The company does not currently own manufacturing facilities and contracts with third parties for product manufacturing and distribution. As a smaller reporting company, Dianthus is classified as a non-accelerated filer with the Securities and Exchange Commission.
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- HQ
- NEW YORK, NY
- FY end
- 12-31
- CIK
- 1690585
- SIC
- 2834
Ownership
Who holds Dianthus Therapeutics, Inc. — across funds, superinvestors and bonds · N-PORT 2026Q2 · 13F 2026-06-30
Top fund holders
| Fund | % of fund | Value |
|---|---|---|
| VANGUARD TOTAL STOCK MARKET INDEX FUND VTI · VANGUARD INDEX FUNDS | 0.01% | $160.83M |
| Fidelity Growth Company Fund FDGRX · Fidelity Mt. Vernon Street Trust | 0.15% | $148.27M |
| State Street(R) SPDR(R) S&P(R) Biotech ETF XBI · SPDR SERIES TRUST | 1.18% | $127.01M |
| iShares Russell 2000 ETF IWM · iShares Trust | 0.14% | $118.40M |
| T. Rowe Price Small-Cap Stock Fund, Inc. OTCFX · T. ROWE PRICE SMALL-CAP STOCK FUND, INC. | 1.21% | $112.64M |
Superinvestors in Dianthus Therapeutics, Inc.
Share of each manager's reported 13F portfolio.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Fund ownership is a subset of institutional 13F ownership — the two describe overlapping populations and must not be added together.
Go deeper in your own AI
15 years of statements, narrative and filings — queryable over MCP.
Professionals can also use the built-in AI chat (subscription + your own Anthropic key).
15 years of Dianthus Therapeutics, Inc.'s financials
Income statement, balance sheet and cash flow across 15 years, every filing with its disclosures, and each number traceable to the filing it came from — free with an account, no card required.
Sign in free